Clinical trials

The primary purpose of this study is to evaluate the effects of CellCore protocols on environmental toxicant biomarkers among adult patients with high baseline toxicant levels. Patients will be allocated to one of two CellCore protocols (Foundational Protocol or BioToxin Binder/Drainage Activator) based on overall physical health, mental health, and fatigue levels at baseline. A prospective, practitioner-led, open-label, single-arm intervention with the CellCore protocols will be conducted to measure pre- and post-intervention changes in urinary environmental toxicant biomarkers and validated, patient-reported health outcomes.

A single-arm, open-label prospective study will be conducted evaluating the impact of 8 weeks of supplementation at the manufacturer-recommended dose of Complete Commensal Probiotic™ on the GI-MAP stool test panel (Diagnostic Solutions Laboratory, Alpharetta, GA), gastrointestinal symptoms, digestion-associated quality of life. and overall physical health, mental health, and anxiety.

The primary purpose of this study is to evaluate cross-sectional associations between mold exposures identified with The Dust Test and self-reported physical health, emotional health, and medical diagnoses. In addition, associations between mold exposures and mycotoxin levels among users who have done mycotoxin lab testing will also be evaluated.

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.